oru.sePublikationer
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Prognostic impact of COX-2 in non-small cell lung cancer: a comprehensive compartment-specific evaluation of tumor and stromal cell expression
Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden.
Department of Respiratory Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden.
Department of Statistics, TU Dortmund University, Dortmund, Germany.
Leibniz Research Centre for Working Environment and Human Factors (IfADo), TU Dortmund University.
Show others and affiliations
2015 (English)In: Cancer Letters, ISSN 0304-3835, E-ISSN 1872-7980, Vol. 356, no 2, 837-845 p.Article in journal (Refereed) Published
Abstract [en]

Cyclooxygenase-2 (COX-2) is an enzyme that has been extensively investigated as a prognostic marker in cancer. In non-small cell lung cancer (NSCLC) previous results regarding the prognostic impact of COX-2 expression are inconsistent. Therefore we evaluated the association between transcript levels and overall survival in nine publicly available gene expression data sets (total n = 1337) and determined in situ compartment-specific tumor and stromal cell protein expression in two independent cohorts (n = 616). Gene expression did not show any correlation with clinical parameters or with overall survival. Protein expression in tumor and stromal cells did not correlate with any clinical parameter or with overall survival in one of the analyzed cohorts, while a significant association of high stromal expression with longer survival was observed in both univariate and multivariate analysis in the other cohort. Stromal expression of COX-2 has not been separately evaluated in NSCLC previously and may be a subject of further investigation, whereas the presented findings from this comprehensive compartment specific evaluation clearly reject the hypothesis of COX-2 tumor cell expression having a prognostic value in NSCLC. (C) 2014 Elsevier Ireland Ltd. All rights reserved.

Place, publisher, year, edition, pages
2015. Vol. 356, no 2, 837-845 p.
Keyword [en]
Cyclooxygenase 2, Lung cancer, PTGS2, Microarray, Prognosis, Immunohistochemistry
National Category
Cancer and Oncology
Research subject
Oncology
Identifiers
URN: urn:nbn:se:oru:diva-42800DOI: 10.1016/j.canlet.2014.10.032ISI: 000348005500057PubMedID: 25449785Scopus ID: 2-s2.0-84919444431OAI: oai:DiVA.org:oru-42800DiVA: diva2:789523
Funder
Swedish Cancer Society
Note

Funding Agencies:

Lions Cancer Foundation Uppsala

German Research Foundation (DFG) RA 870/4-1  RA 870/5-1

Available from: 2015-02-19 Created: 2015-02-19 Last updated: 2017-03-17Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Karlsson, Mats G.Karlsson, ChristinaHelenius, Gisela
By organisation
School of Health and Medical Sciences, Örebro University, SwedenOrebro University HospitalSchool of Medicine, Örebro University, Sweden
In the same journal
Cancer Letters
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 327 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf